HEADER RECORD*******LIBRARY HEADER RECORD!!!!!!!000000000000000000000000000000 SAS SAS SASLIB 9.4 Linux 31MAR21:12:06:0931MAR21:12:06:09 HEADER RECORD*******MEMBER HEADER RECORD!!!!!!!000000000000000001600000000140 HEADER RECORD*******DSCRPTR HEADER RECORD!!!!!!!000000000000000000000000000000 SAS TA SASDATA 9.4 Linux 31MAR21:12:06:0931MAR21:12:06:09 Trial Arms HEADER RECORD*******NAMESTR HEADER RECORD!!!!!!!000000001000000000000000000000 STUDYID Study Identifier DOMAIN Domain Abbreviation ARMCD Planned Arm Code ARM Description of Planned Arm TAETORD Planned Order of Element within Arm 0ETCD Element Code 8ELEMENT Description of Element @-TABRANCHBranch T; TATRANS Transition Rule EPOCH Epoch ¼ HEADER RECORD*******OBS HEADER RECORD!!!!!!!000000000000000000000000000000 C4591001TAB1_10 BNT162b1 Phase 1 (10 mcg) ASCRN Screening Randomized to B1_10 SCREENING C4591001TAB1_10 BNT162b1 Phase 1 (10 mcg) A VAXB1_10BNT162b1 (10 mcg) VACCINATION C4591001TAB1_10 BNT162b1 Phase 1 (10 mcg) A0FUP Follow-up FOLLOW-UP C4591001TAB1_100 BNT162b1 Phase 1 (100/10 mcg)ASCRN Screening Randomized to B1_100 SCREENING C4591001TAB1_100 BNT162b1 Phase 1 (100/10 mcg)A VAXB1100BNT162b1 (100 mcg) VACCINATION C4591001TAB1_100 BNT162b1 Phase 1 (100/10 mcg)A0VAXB1_10BNT162b1 (10 mcg) VACCINATION C4591001TAB1_100 BNT162b1 Phase 1 (100/10 mcg)A@FUP Follow-up FOLLOW-UP C4591001TAB1_20 BNT162b1 Phase 1 (20 mcg) ASCRN Screening Randomized to B1_20 SCREENING C4591001TAB1_20 BNT162b1 Phase 1 (20 mcg) A VAXB1_20BNT162b1 (20 mcg) VACCINATION C4591001TAB1_20 BNT162b1 Phase 1 (20 mcg) A0FUP Follow-up FOLLOW-UP C4591001TAB1_30 BNT162b1 Phase 1 (30 mcg) ASCRN Screening Randomized to B1_30 SCREENING C4591001TAB1_30 BNT162b1 Phase 1 (30 mcg) A VAXB1_30BNT162b1 (30 mcg) VACCINATION C4591001TAB1_30 BNT162b1 Phase 1 (30 mcg) A0FUP Follow-up FOLLOW-UP C4591001TAB2_10 BNT162b2 Phase 1 (10 mcg) ASCRN Screening Randomized to B2_10 SCREENING C4591001TAB2_10 BNT162b2 Phase 1 (10 mcg) A VAXB2_10BNT162b2 (10 mcg) VACCINATION C4591001TAB2_10 BNT162b2 Phase 1 (10 mcg) A0FUP Follow-up FOLLOW-UP C4591001TAB2_20 BNT162b2 Phase 1 (20 mcg) ASCRN Screening Randomized to B2_20 SCREENING C4591001TAB2_20 BNT162b2 Phase 1 (20 mcg) A VAXB2_20BNT162b2 (20 mcg) VACCINATION C4591001TAB2_20 BNT162b2 Phase 1 (20 mcg) A0FUP Follow-up FOLLOW-UP C4591001TAB2_30 BNT162b2 Phase 1 (30 mcg) ASCRN Screening Randomized to B2_30 SCREENING C4591001TAB2_30 BNT162b2 Phase 1 (30 mcg) A VAXB2_30BNT162b2 (30 mcg) VACCINATION C4591001TAB2_30 BNT162b2 Phase 1 (30 mcg) A0FUP Follow-up FOLLOW-UP C4591001TAB2_P23_30BNT162b2 Phase 2/3 (30 mcg) ASCRN Screening Randomized to B2_P23_30 SCREENING C4591001TAB2_P23_30BNT162b2 Phase 2/3 (30 mcg) A VAXB2_30BNT162b2 (30 mcg) VACCINATION C4591001TAB2_P23_30BNT162b2 Phase 2/3 (30 mcg) A0FUP Follow-up FOLLOW-UP C4591001TAPLACEBO Placebo ASCRN Screening Randomized to PLACEBO SCREENING C4591001TAPLACEBO Placebo A VAXP Placebo If subject is OL eligible then go to TAETORD 4 VACCINATION C4591001TAPLACEBO Placebo A0FUP Follow-up FOLLOW-UP C4591001TAPLACEBO Placebo A@SCRNOL Screening Open LabelEligible subjects assigned to B2_30 treatmentIf repeat screening not completed/failed, go to TAETORD 3REPEAT SCREENING 1 C4591001TAPLACEBO Placebo APVAXB2_30BNT162b2 (30 mcg) OPEN LABEL TREATMENTC4591001TAPLACEBO Placebo A`FUPOL Follow-up Open Label OPEN LABEL FOLLOW-UP